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Abstract
Background: Centralization of IRB reviews have been increasing in the US and elsewhere, but many questions
about it remain. In the US, a few centralized IRBs (CIRBs) have been established, but how they do and could
operate remain unclear.
Methods: I contacted 60 IRBs (every fourth one in the list of the top 240 institutions by NIH funding), and
interviewed leaders from 34 (response rate = 55%) and an additional 12 members and administrators.
Results: These interviewees had often interacted with CIRBs, but supported local reviews, and offered advantages
and disadvantages of each. Interviewees argued that local IRBs can provide “local knowledge” of subjects and PIs,
and “curbside consults” with PIs, facilitating mutual trust. PIs may interact more fully and informally, and hence
effectively with local IRBs. IRBs also felt additional responsibility to protect “their own” subjects. Respondents
mentioned a few advantages of CIRBs (e.g., CIRBs may streamline reviews), though far more rarely and cursorily.
Overall, interviewees were wary of CIRBs, which they saw as varying widely in quality, depending on who
happened to be members. Both local and centralized IRBs appear to have unintended consequences. For instance,
discrepancies arose between IRBs that appeared to reflect differences in institutional culture and history, and
personalities of chairs and/or vocal members, more than in local community values per se, and thus do not seem
to be the intent of the regulations. While some critics see CIRBs as solutions to many IRB problems, critical
tradeoffs and uncertainties emerge.
Conclusions: These data have critical implications for future policy and research. Debates need to evolve beyond
simply a binary discussion of whether CIRBs should replace local IRBs, to examine how and to what degree
different models might operate, and what the relative advantages and disadvantages of each are. While some
critics see CIRBs as panaceas, certain problems appear likely to continue. Careful consideration needs to be given
to whether the advantages of local IRBs outweigh the problems that result, and whether a system can be
developed that provides these benefits, while avoiding the disadvantages of local IRBs.
Background
Centralization of reviews by Institutional Review Boards
(IRBs) in the US, and Research Ethics Committees
(RECs), as they are called in many other countries, have
been increasing in several areas of the world, but many
questions about this trend remain. The European Union
(EU) has sought to harmonize reviews of clinical trials
across RECs in member countries, yet responses within
individual countries have varied [1-5]. Within EU coun-
tries, central, regional, and local RECs often exist, and
tensions between these have arisen, including debates
on how, and to what degree to unify processes and deci-
sions [1].
In the US as well, several centralized IRBs (CIRBs)
have been established, generating controversies and
questions about how they do and should operate. CIRBs
can be either governmental bodies or private for-profit
commercial entities. These two varieties differ in certain
key regards - e.g., in purpose, and potential conflicts of
interest. Yet similarities exist in that both have been
established as alternatives to perceived limitations of
local IRBs.
Critics have argued that the current system of review
is flawed [6]. In particular, documented discrepancies in
IRB reviews of multi-site studies have led many critics
to call for far more use of CIRBs - presumably through
governmental or other non-profit mechanisms [7]. Such
discrepancies can require changes in protocols that Correspondence: rlk2@columbia.edu
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difficult to compare.
Yet in the US, CIRBs, though proposed over the past
15 years [8,9], have been instituted only to relatively
limited extents [10], and resistance has arisen. Several
models of CIRBs have been suggested for multi-site stu-
dies, generally allowing local IRBs to accept, reject, or
amend these CIRB reviews. But it is not clear whether
such increased centralization will occur, and if so, to
what degree, how, and when. These issues are signifi-
cant, since the impact, outcomes, and effectiveness of
CIRBs will doubtlessly affect whether they are more
widely adopted.
In a recent in-depth semi-structured interview study I
conducted of views and approaches toward research
integrity (RI) among IRB chairs, directors, administrators,
and members [11], issues concerning CIRBs repeatedly
arose. The study aimed to understand how IRBs viewed
RI, which these participants defined very broadly. Inter-
viewees revealed how they defined, viewed, and addressed
integrity in research, and responded to violations of RI in
a wide variety of ways, related to how they saw and
approached the roles and responsibilities of IRBs; inter-
preted and applied federal regulations; viewed and inter-
acted with researchers, federal agencies, institutions, and
industry funders; and were affected by histories of viola-
tions of RI and audits at their own and other institutions,
and psychological and personality issues on their IRB
[12]. They varied on whether additional guidelines and
regulations would be helpful, and if so, what, where, and
w h y ;a n dh o wt h e yr e l a t e da n dr e s p o n d e dt op r i n c i p l e
investigators (PIs), tried to improve these relationships,
responded to tensions and complaints concerning IRBs,
and interfaced with researchers in the developing world
[13]. Issues frequently arose concerning how IRBs dif-
fered, and whether CIRB mechanisms might be advanta-
geous or disadvantageous, and how, when, and why.
S i n c et h es t u d yu s e dq u a l i t a t ive methods, it allowed for
further detailed explorations of domains that emerged,
shedding light on these issues.
A few studies have probed logistical aspects of IRBs (e.
g., sociodemographics of members, and length of time
that transpires before approval) [7,14,15]. One study
found that CIRBs reduce time, staff effort, and costs
[16], though the quality of reviews was not assessed. Yet
CIRBs have encountered resistance. Among medical
school IRBs, 76% have never used a CIRB, and 73%
thought there was no reason to do so since their local
IRB worked efficiently [17]. Surprisingly, no published
studies have systematically examined how local IRBs
view and experience CIRBs. Thus, this paper examines
IRB chairs, staff, and members’ attitudes and interac-
tions with CIRBs - how these individuals have viewed
and interfaced with these entities, and what they
perceive to be the advantages and disadvantages of each
of these two mechanisms for review.
Methods
As described elsewhere [11-13], I conducted in-depth
telephone interviews of 2 hours each with 46 chairs,
directors, administrators, and members. I contacted the
leadership of 60 IRBs around the country, representing
every fourth one in the list of the top 240 institutions
by NIH funding, and interviewed IRB leaders from 34 of
these institutions (response rate = 55%). In some cases,
I interviewed both a chair/director and an administrator
from an institution (e.g., as the chair thought that the
administrator might be better able to answer certain
questions). From these 34 institutions, I thus inter-
viewed a total of 39 chairs/directors and administrators.
The institutions range in location, size, and public/pri-
vate status. Inclusion of IRBs from a wide range of insti-
tutions allowed for illumination of the roles of different
social and institutional contexts on these issues. I also
asked half of these leaders (every other one on the list
by amount of NIH funding) to distribute information
about the study to members of their IRBs, in order to
recruit 1 member of each of these IRBs to be inter-
viewed for the study as well. Thus, in addition to the 39
chairs/directors and administrators, I interviewed 7
other members (6 regular members and 1 community
member) as well.
As summarized in Table 1, these 46 individuals
include 28 chairs/co-chairs; 1 IRB director; 10 adminis-
trators (including 2 directors of compliance offices); and
7 members. In all, 27 were male and 19 were female. 1
was Asian/Pacific Islander, while the remaining 43 were
Caucasian. 21 came from institutions in the Northeast, 6
from the Midwest, 13 from the West, and 6 from the
South. From institutions ranked 1-50, 51-100, 101-150,
151-200, 201-250 in NIH funding, the number of inter-
viewees were 13, 13, 7, 1, and, 12, respectively.
The interviews focused on differences in participants’
views of integrity of research, broadly defined, and in
IRB responses to problems in these realms, and factors
involved, and shed important light on many other,
related issues as well that arose concerning IRBs’ deci-
sions, and relationships with PIs and each other, local
vs. centralized IRBs. Interviews then explored these
domains in further depth. Relevant sections of the inter-
view guide are attached (see Appendix A), through
which we sought to obtain detailed descriptions of the
above issues. From a theoretical standpoint, Geertz [18]
has advocated studying aspects of individuals’ lives, deci-
sions, and social situations not by imposing theoretical
structures, but by trying to understand the individuals’
own experiences, drawing on their own words and per-
spectives to obtain a “thick description.”
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theory [19], as I have used and described in several
prior studies [20-22]. This approach was thus informed
by techniques of “constant comparison,” in which data
from different contexts are compared for similarities
and differences to see if they suggest hypotheses. This
technique of “constant comparison” generates new ana-
lytic categories and questions, and checks them for rea-
sonableness. During the ongoing process of in-depth
interviewing, how participants resembled or differed
from each other, and how social, cultural, and medical
contexts and factors contributed to these differences, are
constantly considered. Grounded theory also involves
both deductive and inductive thinking, building induc-
tively from the data to an understanding of themes and
patterns within the data, and deductively, drawing on
frameworks from prior research and theories.
In conducting thematic content-analyses, I also trian-
gulated methods, referring to the published literature, as
described above. I drafted the questionnaire, drawing on
prior research I conducted and published literature.
Transcriptions and initial analyses of interviews
occurred during the period in which the interviews were
being conducted, enhancing validity, and these analyses
helped shape subsequent interviews. The Columbia Uni-
versity Department of Psychiatry Institutional Review
Board approved the study, and all participants gave
informed consent.
Once the full set of interviews were completed, subse-
quent analyses were conducted in two phases, primarily
by a trained research assistant (RA) and me. In phase I,
the RA and I independently examined a subset of inter-
views to assess factors that shaped participants’ experi-
ences, identifying categories of recurrent themes and
issues that were subsequently given codes. We read
each interview, systematically coding blocks of text to
assign “core” codes or categories (e.g., instances of IRBs
interacting with CIRBs, and views of CIRBs). While
reading the interviews, a topic name (or code) was
inserted beside each excerpt of the interview to indicate
the themes being discussed. We then worked together
to reconcile these independently developed coding
schemes into a single scheme. We then prepared a cod-
ing manual, defining each code and examining areas of
disagreement until reaching consensus between them.
New themes that did not fit into the original coding fra-
mework were discussed, and modifications were made
in the manual when deemed appropriate.
In phase II of the analysis, an RA and I then indepen-
dently performed content analysis of the data to identify
the principal subcategories, and ranges of variation
within each of the core codes. The sub-themes identified
by each coder were reconciled into a single set of “sec-
ondary” codes and an elaborated set of core codes.
These codes assess subcategories and other situational
and social factors. Such subcategories include, e.g., per-
ceived advantages and disadvantages of CIRBs - such as
possession of local knowledge of PIs.
Codes and sub-codes were then used in analysis of all
of the interviews. Two coders analyzed all interviews.
Where necessary, multiple codes were used. We
assessed similarities and differences between partici-
pants, examining categories that emerged, ranges of var-
iation within categories, and variables that may be
involved.
We examined areas of disagreement through closer
analysis until reaching consensus. We checked regularly
for consistency and accuracy in ratings by comparing
earlier and later coded excerpts. To ensure that the cod-
ing schemes established for the core codes and second-
ary codes are both valid and reliable (i.e., consistent in
meaning), they were systematically developed and well-
documented. In this proces s ,w ew e r ea b l et oe x p l o r e
“cases” of problems that arise (e.g., difficult decisions
IRB chairs faced), to examine the range and patterns of
issues that emerge.
Table 1 Characteristics of the Sample
Total % (N = 46)
Type of IRB Staff
Chairs/Co-Chairs 28 60.87%
Directors 1 2.17%
Administrators 10 21.74%
Members 7 15.22%
Gender
Male 27 58.70%
Female 19 41.30%
Institution Rank
1-50 13 28.26%
51-100 13 28.26%
101-150 7 15.22%
151-200 1 2.17%
201-250 12 26.09%
State vs. Private
State 19 41.30%
Private 27 58.70%
Region
Northeast 21 45.65%
Midwest 6 13.04%
West 13 28.26%
South 6 13.04%
Total # of Institutions Represented 34
Klitzman BMC Medical Ethics 2011, 12:13
http://www.biomedcentral.com/1472-6939/12/13
Page 3 of 14Results
Several themes emerged concerning advantages and
disadvantages of local vs. centralized IRBs. Table 2
summarizes these themes (which reflect critical codes
and sub-codes used in the data analysis). In brief, all of
these interviewees favored local over centralized
reviews. They had all confronted challenges concerning
multi-site studies, and were very aware of issues con-
cerning CIRBs. Most had interacted with centralized,
for-profit IRBs (e.g., Western IRB), and several had
worked with governmental CIRBs as well. Most had
attended national IRB meetings (e.g., of PRIM&R) -
where these issues are often discussed - and interacted
with colleagues at other institutions, and thus, had
experience with CIRBs directly and/or indirectly. Over-
all, they offered six broad advantages of local reviews,
and three limitations of CIRBs. One advantage of
CIRBs and one disadvantage of local reviews also
arose.
These interviewees’ beliefs and perceptions of the
advantages and disadvantages of local vs. centralized
reviews are not necessarily objectively “accurate” and/or
always justified, but are nonetheless important, shedding
light on difficulties that emerge, and will no doubt con-
tinue to do so, in attempts to alter the status quo.
Perceived Problems and Ambivalence Concerning Local
IRBs
Almost all interviewees strongly defended the current
system, though a few described themselves as “IRB
critics,” mentioning flaws in the status quo. Still, in the
end, even these relative skeptics supported local
approaches. As one chair said,
The whole IRB system is a mess. There are now over
5,000 IRBs in this country, and if you are a company
trying to place your protocol in individual institu-
tions, that can drive you nuts. It’s terrible. IRB4
But ultimately, even this chair supported a local,
rather than centralized or regional system, to maximize
the quality of reviewing and protection.
However, I feel very strongly that the closer you get
to the actual subjects, the better review you get, and
the better you can protect the rights and safety of
the subjects. IRB4
A few interviewees took a more balanced, and perhaps
nuanced view, and felt that the status quo has both
strong advantages and disadvantages that need to be
carefully considered and weighed.
We have a very decentralized system that gives a lot
of responsibility and flexibility to local IRBs, which
is a blessing and a curse. IRB18
Yet in the end, these respondents, too, favored conti-
nuation of local review.
Table 2 Views of Local IRBs Regarding CIRB Review
Perceived Problems and Ambivalence Concerning Local IRBs
▪ Problems concerning local IRBs often recognized
▪ But general wariness of CIRBs, and support for local IRBs
Perceived Advantages of Local IRBs
▪ Claims that local IRBs reflect community values
▪ Local knowledge of subjects
◦ Of vulnerable populations
◦ Therefore, easier to judge risks and benefits
▪ Local knowledge of PIs
◦ “Track records"/reputations
▪ Protecting “our own” subjects
◦ Perceived responsibilities to protect local patients
▪ “Curbside consults” with PIs
◦ Formal and informal
◦ Can facilitate mutual trust
◦ More dialogue
◦ Appreciation of local institutional culture
▪ Desires for local autonomy, authority, and comfort
◦ Against “being told what to do”
◦ Wariness of centralized, federal bureaucracy
Perceived Problems with CIRBs
▪ Differences between CIRBs
◦ Depends on who are members of the committee
▪ For-profit CIRBs may have conflicts of interest
Advantages of CIRBs
▪ Rarely acknowledged
▪ Streamlining work
◦ Saving Time
Disadvantages of Local IRBs
▪ Discrepancies can arise due to:
◦ Institutional culture and history
◦ Personalities
Local Members as Biased in Their Views of CIRBs?
Other Possible Solutions
▪ More guidance
▪ More regional IRBs?
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Claims that local IRBs reflect community values
Several interviewees were conflicted, but ultimately felt
that local IRBs were essential because these provided
input concerning local community values. Frequently,
interviewees claimed that local IRBs could uniquely
reflect differences in local community values.
A centralized IRB system for multi-site studies
sounds like a good idea, but the local research con-
text and the community attitudes towards research
still need to be checked. I’m torn about that, because
there’s tension. It would be good and efficient to
h a v eo n eb o d yw i t ha l lt h ei n f o r m a t i o n ,p r o v i d i n g
oversight and monitoring. But somebody out there
in Timbuktu could screw up, or do something inap-
propriate to that culture, and nobody would know.
You wouldn’t have a local community member say-
ing: “This will never fly in my community.” So, a
centralized mechanism doesn’tg e ty o ua w a yf r o m
the problem of having to go through multiple hoops.
IRB26
This administrator cites the importance of contrasting
community attitudes, but of note, invokes the notion of
“Timbuktu” - a foreign exotic locale. She uses potential
cross-national variations to argue that potential domes-
tic differences exist as well to justify local IRB review in
the US.
Occasionally, interviewees offered examples of what
they felt were differences between communities. For
instance, one chair in a rural area saw a contrast
between rural and urban areas, each having varying per-
ceptions of research. He thought that patients in his
community were more likely to decline participation.
In my own research, it is very difficult to recruit
people for anything invasive. In the city where I
trained, we did the same level of invasive studies,
but people just kind of understood this research: I’m
volunteering. Here, you have to explain yourself
more: this is what research means, this is the impor-
tance of doing it. Not with everybody. But with the
occasional study participant, it just takes a little
more effort to give them the confidence that it’s OK.
A lot of it has to do with it being a rural community
- less of a big city. Here, everybody knows each
other. But research just isn’tu n d e r s t o o da si nab i g
urban center, due to exposure in everyday life. Here,
the newspaper has articles about farming, and on a
far distant page, about science. IRB27
Yet, the differences he suggests appear to be due to
awareness and education, not necessarily contrasts in
underlying community values per se. Rural and urban
regions may also range in logistical factors. He contin-
ued,
There’s sort of an identity here of rugged individual-
ism, but I don’t think that’s what gets in the way. It’s
just lack of awareness, exposure, and understanding
of the importance of research. Part of it though is
that some people would have to drive three hours to
get here, and that’s just not feasible. IRB27
Thus, perceived variations may arise not from differ-
ences in local moral values, but from other geographic
factors. Indeed, the same proportion of the population
may be interested in research in both locales, but rural
areas simply have fewer patients overall. Hence, more
populous regions have higher absolute numbers of inter-
ested participants. Yet no interviewees provided clear
instances of differences in local community values.
Local knowledge of subjects
In supporting local, as opposed to centralized, boards,
almost all interviewees cited advantages of “local knowl-
edge” - e.g., knowing about local subjects. Indeed, only a
local IRB may know certain unstated details about a
protocol, such as the fact that a particular institution
primarily serves a disadvantaged population.
In one study of parenting skills for moms, the ratio-
nale was to show how young moms, living alone
without the benefit of several generations to help
them, didn’t know anything about comfort care - lul-
laby singing, story-telling, rocking chairs with fussy
babies. But the hospital they picked was a private
hospital that only accepts private pay patients. The
p a t i e n t sw h oc o u l db e n e f i tm o s tf r o mt h es t u d y
were indigent patients in clinics. We asked: are
those individuals really going to be at this private
hospital? One co-investigator saw patients only at
that hospital, and had quite a bit of influence. We
urged them - we cannot insist that a study be con-
ducted at a specific hospital. But if the objectives are
for a particular population who can’tt a k ea d v a n t a g e
of the study, I think, it’s within the IRB purview to
say, would you be willing to offer this study to peo-
ple who are not patients there - advertise it through
clinics or hospitals where these other patients would
be able to access it? On the surface, the protocol
met almost all of the requirements. Their objective
was well stated, but that’s where the local oversight
comes in - if you didn’t know that that hospital only
accepted private pay patients. IRB13
Only a local IRB might know that a particular hospital
serves a population that is vulnerable in other ways as
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As another chair explained,
If I am going to recruit all my patients from a cer-
tain psychiatric center, a colleague here in town
would know exactly what I’m talking about, and
who those patients are - and their demographics.
That kind of local knowledge. If you are accused of a
crime, you want to be judged by a jury of your peers,
n o tb ys o m e b o d yw h oh a st h es a m ed e m o g r a p h i c
from halfway across the country. IRB12
This chair draws analogies to juries that presumably
consist of one’s peers. He suggests that “peers” are based
not on demographics alone, but on other characteristics -
shared knowledge of a community. This chair sees
importance in knowing details about a population - hav-
ing a sense of familiarity that is concrete, not abstract.
The farther away you get from the actual group of
subjects, the harder it is for a committee to judge the
risks and benefits. So in our IRB, we are thinking
about whether it’s ethical and reasonable to do a
study of new asthma treatments for young black
children in our city. This is not abstract. We all
know exactly who’si n v o l v e d ,w h a tthe lives of those
individuals are like, what the protocol could offer
them. An IRB in another state could not make as
informed a decision. IRB12
Ideally, centralized or regional IRBs should be able to
request and assess such details, but his comment high-
lights challenges CIRBs may face.
Local Knowledge of PIs
Local knowledge can also extend to IRBs knowing local
PIs’ individual characters, personalities, and past experi-
ences.
The most effective IRBs are those in an institution
where the reviewers are familiar with the work and
integrity of the researcher. That is the most impor-
tant element, other than the actual research proposal
itself. What’s this researcher’s track record?H a sh e
been shot down once or twice? Regional IRBs might
get reports of that info, but don’t have the personal
understanding, feel,a n dflavor that’sn e e d e df o ra
heightened level of review. Regional IRBs may be
administratively effective and sound, but focus on
cooperative group research, clinical trial groups, can-
cer groups. They are good for a subset of clinical
trials. IRB9
This interviewee suggests a higher standard here - a
“heightened level of review” -t h a to n l yal o c a lI R Bc a n
provide. Yet questions arise of what this level consists
of; how “heightened” it is; when it is needed and/or fea-
sible, and to what degrees; and in what ways knowledge
of the PI does or should influence reviews.
In reviews, notions of “feel” and “flavor” thus arise,
suggesting subjective, almost aesthetic qualities involved.
Such local knowledge about PIs can include subjective
impressions and suspicions concerning their integrity
and views of, and respect for the IRB. For instance, local
PIs may try to use their power and influence to affect
IRB decisions, which can then make the IRB wary about
future interactions. An IRB may feel that these efforts
shape deliberations and indicate deep disrespect.
When a PI tried to exercise his power, as a vice-
dean, and convince the IRB to review a study favor-
ably, his future submissions were questioned. It’sa n
integrity issue: he’s exercising a position of influence,
which contributes to the appearance of coercion.
That’s when the research Compliance Office comes
in. That happens rarely - not in three years. It’s
usually low risk research. The PI may use the “no
harm, no foul“ principle: “I did all this research with-
out IRB review. I now know I need IRB approval.
B u tn oo n eg o th u r t .W h a t ’s the big deal? Give me
retroactive approval.” Obviously, we can’t. But it
doesn’t stop there. One person came back and said,
“You’re going to screw me up, ruin my publication,
tarnish my reputation.” Mea culpa is one thing. We
approve use of the data, but don’tg i v er e t r o -
approval. We are sympathetic, but can’t bend to that
type of coercion. An IRB decision cannot be over-
turned by anyone in the institution. That’st h ei n d e -
pendence given by the regulations. IRB9
The IRB may then examine that researcher’ss u b s e -
quent studies more closely. This IRB director continued,
We look at that PI’s future research a little more
cautiously. Because that PI is willing to try and con-
vince his peers to make an exception for him
because of who he or she is. IRB9
Personal knowledge of a local PI can thus potentially
sway assessments of a protocol, yet prejudice may exist
either positively or negatively. Questions then surface as
to how important that past experience is or should be -
whether such added future vigilance might ever go too
far, and whether each protocol should instead be
reviewed on its own merits alone (as with blinded peer-
reviews of scientific journal articles), unaffected by
whom the researcher happens to be.
Moreover, in reviewing a protocol, personally knowing
the PI can potentially not only help, but create tensions,
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direct or indirect pressure to approve his or her study.
Protecting “our own” subjects
Many interviewees felt a particular bond and responsi-
bility to protect the patients at their own institution. In
part, as clinicians, many interviewees felt obligations
toward their patients.
With the local approach, we absolutely feel com-
mitted to the subjects in this area. A lot of them are
our patients.T h e ya r ef r o mt h ec o m m u n i t yt h a tw e
are committed to serving. That commitment
couldn’t be higher. I would worry that if the IRB
became more regionalized, de-personalized and, par-
ticularly, for-profit, that would go away at little bit. I
am not sure. IRB40
Thus, for IRBs, a sense of professional, social, and
geographic closeness at times appeared to heighten a
sense of moral obligation. As a result, interviewees
expressed added wariness of CIRBs.
As suggested earlier, IRBs often feared centralized
bodies as “anonymous bureaucrats in Washington.” This
attitude reflects in part a sense of bonds, and being part
of a local community, but also stemmed from a general
wariness of federal government involvement, with its
innate anonymity.
Centralized IRBs may be a solution, but we really
want to know what’s going on on our campus -
what’s being said, conveyed to our community,a n d
participants. It would be hard for people to say, “Oh,
this was approved by some anonymous body, so it
should be OK.” IRB27
“Curbside consults” with PIs
Though federal regulations established IRBs as local,
presumably to reflect local laws and standards, unin-
tended benefits emerge - that PIs can interface with the
IRB both formally and informally, facilitating interac-
tions. Knowing the local “gatekeeper” (i.e., the IRB) has
advantages.
The concept of local IRBs was to get local cultural
input into the review of studies in a particular com-
munity. I suspect that that’s less of an issue in very
white and affluent areas like ours. It might be a very
big issue in Alabama. I think Tuskegee could have
been very different. So, the basic philosophical pre-
mise of local IRBs is very good. I like the decentrali-
zation, not because I like repeating all the work, but
because I’mn o ts u r eIw o u l dtrust ac e n t r a lI R B
somewhere in Washington. I don’t think it was the
intent, but the practical outcome of local IRBs is
that PIs bounce stuff off me all the time. The concept
of an IRB helping to inform the design of research as
well as being a gatekeeper is good, though I’mn o t
sure that was ever intended. IRB14
IRBs can thus interact with PIs informally and in per-
son, rather than through the constrictions of formal
memos back and forth. Such informal verbal communi-
cation can allow PIs to present possible approaches (e.g.,
“what if I did X?”), while inherent constrictions of for-
mal memos might impede such interactions. Informal
conversations can thus help shape studies early on, clari-
fying what research approaches may be ethically proble-
matic before they are more elaborately pursued. This
interviewee also mentions the underlying desire for trust
- of CIRBs and PIs - which is important, but can be fra-
gile. Informal local feedback has the advantage, too, of
being readily available.
Researchers say, “What do you think of this?” Is a y ,
“I can tell you: ‘We’re going to make you do this,’
‘say X.’‘ No, you can’t give the pharmacist a finder’s
fee to identify how many patients are getting this
drug.’” Or, we’ll get an informed consent, and say,
“Our IRB likes to see the wording a certain way.
Email me, and we’ll send it back to you.” It is good
to have the local cooperative mechanism. IRB14
Trust and a sense of mutual commitment can thus be
increased.
Curbside consults can allow PIs, too, to explore the
possibility of changing protocols already approved - e.g.,
making exceptions to include patients who do not
exactly fit the pre-established criteria or timeline. These
changes might not alter the direct risks or benefits to
the subject, but the indirect social benefits of the
research, about which local IRBs can thus readily inform
PIs.
The most frequent curbside thing I have to deflect,
and say OK, we need paperwork for this, is: “This
patient fits the study really well, except for this one
really little glitch. Can I put him in the study any-
way? The protocol says within four weeks. It’sb e e n
four weeks and three days.” That’sw h e nIp u s h
back. With investigator-initiated studies, researchers
then say, “It doesn’t really make any difference, but I
had to write something in the protocol.” Ia n s w e r :
“If that rule was important enough to write down,
w h yi si tO Kt ob r e a ki t ?I fi t ’sO Kt ob r e a ki t ,
maybe you should rewrite the rule to reflect reality.”
Id ot h a tal o t-n o ts om u c ht r y i n gt op r o t e c tt h e
subject from risk, but protecting the science from
damage. If you make all these exemptions, you are
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get uninterruptible results, it puts the science at risk.
Usually, it’s not serious, but a couple times I’ve said,
“This is the fifth time you’ve asked me about this.
Rewrite the protocol, rather than making all these
exemptions. If this is an important rule, you can’t
break it.” They then have to convince me that it’s
OK. Because otherwise, thinking ahead, the paper’s
method section says “patients will have had a CT
scan no more than four weeks ago.” And I’ll say,
“That’sn o tt r u e . ” This is small stuff, but it’so fa
piece of real falsification of data. IRB14
Though the content of the disagreement here does not
concern differences in local community values, local
IRBs can potentially facilitate the process of interactions,
allowing far more informal “give and take.” These closer
and more frequent interactions can also enhance PIs’
education, and potentially diminish the likelihood of PIs
making potentially problematic changes without notify-
ing the IRB.
Local chairs’ interactions with colleagues can enable
the former, too, to hear about researcher’s difficulties
and struggles, and may enhance IRBs’ understandings of
the strains researchers confront.
I hobnob with colleagues. I hear the woes of our
local cancer investigator over audits in big coopera-
tive studies. IRB14
Improved mutual understanding between IRBs and PIs
can help mollify ongoing tensions that can exist.
At institutions that focus on just one medical speci-
alty, disease, or organ - whether cancer or diabetes -
IRBs will also understand this specific area of medicine,
which can be helpful. As one interviewee from such a
specialty institution said:
A lot of researchers here would be upset if we did
away with our IRB. Here, people understand this
specific area of research - the terms and concepts.
IRB8
Still, regulations mandate that all IRBs have appropri-
ate specialization for reviewing all protocols.
Desires for local autonomy, authority, and comfort
IRBs may also want to review a protocol on their own
because they need to undergo their own cognitive and
emotional processes to become familiar and comfortable
with the issues involved.
Each IRB has its own learning curve,a n dc o m e st o
its own sense about an issue. I could call up the IRB
administrator and say, “We’ve been through this.
This is how we see it. This is how it is.” They would
say, “Thank you very much. We’re going to go figure
it out for ourselves.” Like anybody, we don’t like
other people telling us how to run our own shop -
although it should count for something that another
IRB has approved it. I don’t know how you can
streamline that. It is inevitable. IRB26
IRBs’ decisions can thus involve complex cognitive
and emotional processes, and IRBs may not like to be
told how to proceed. However, this statement suggests,
too, that local control and potentially liability, not local
community values, may at least in part underlie IRB
preferences for local review.
Perceived Problems with CIRBs
Differences between CIRBs
Several interviewees had had experience with more than
one CIRB, particularly for cancer trials with adults or
children, and perceived critical variations. Problems
arose with these entities, due not to the underlying con-
cept of such centralization, but to the specific realities
of who exactly is on each board, what training they have
had, and how “reasonable” they were. Chairs and mem-
bers of CIRBs, like those of local IRBs, could have their
own personalities and idiosyncrasies that can shape their
approaches to studies.
Two-tiered models exist - whereby local institutions
can accept, reject, or modify a CIRB review - but can
still pose challenges.
Id o n ’t want to lose individual input at the level
where the study takes place. The state IRB, estab-
lished by NCI with adults, represents one of the
more logical approaches to review, taking relatively
little time, and still allowing local input. We still
have an option of altering, overriding, or rejecting
the central CIRB action. IRB4
Yet individual CIRBs may themselves differ signifi-
cantly. A more centralized IRB could even be stricter
than a particular local one. One city-wide IRB was more
obsessive than one institution’s own board.
In our city, research involving people covered by Med-
icaid and Medicare has to go through a city IRB,
which puts more control on you. It requires more and
more time and paperwork, and can get crazy, particu-
larly for behavioral research. They often set an even
tighter set of rules, and just keep coming back with
more questions in whatever you do. The city IRB is
primarily laypeople, and they are very, very thorough.
Some of these members have four pages of handwrit-
ten notes on a very small study. It’s too much. IRB25
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tric cancer IRB is not as good as the adult one.
A model is only as good as the quality of the
reviewer. I have absolutely rejected, refuse to become
a part of a similar program with Children’s Oncology
Group because the quality just isn’t there. IRB4
This chair felt that the pediatric CIRB ended up with
overly complicated consent forms.
Children’s Oncology Group’s IRB has a sort of dicta-
tor syndrome. No one gives them feedback, while the
adult CIRB listens to feedback and is not like that.
IRB4
Each IRB, even if centralized, may vary, and have par-
ticular approaches and notions concerning informing
the participants. This chair continued:
In pediatrics, the quality of the consent forms - the
way they present information - pales in comparison
to the adult CIRB’s. The Children’s Group forms are
not user-friendly enough, and do not convey infor-
mation as it could be. Perhaps the pediatric group
has bent over too far backwards, offering complex
charts, with medical jargon of potential drug side
effects. Some of the consent forms just leave my
head spinning. They present facts,n o tinformation.
IRB4
This distinction of facts vs. information highlights the
different functions of each. Information is meant to
“inform,” to create a sense of understanding in the reci-
pient’sm i n d ,w h i l e“facts” implies nothing about the
recipient whatsoever. Yet to decide how to “inform” vs.
merely “present facts,” and what is “user-friendly
enough” can be hard, and in the end, somewhat
subjective.
Several other chairs also preferred the adult, rather
than the pediatric, CIRB, and the fact that IRBs can
choose to accept or alter the adult board’sr e v i e w s ,
prompting support of at least some centralization.
CIRB pass-throughs, mostly from the NCI’s coopera-
tive group studies, have helped streamline our work.
The discussion notes are high quality, and we can
choose to accept their reviews. That would be a
good way of reviewing studies regularly. IRB14
The differences though between the adult and pedia-
tric CIRBs may result in part from historical reasons. It
was noted that the adult CIRB took time and sought
input, while the pediatric group appeared pressured to
quickly do the same.
Four years before the adult CIRB launched, they
asked for input. They had draft after draft of how to
go about doing what they wanted to do. They did it
very cautiously, with relatively few members, to test
the waters, and it turned out very well. I think the
Children’s Oncology Group was simply pressured to
follow suit, but did so without having the requisite
background and preparation. IRB4
Perceptions of the pros and cons of CIRBs depend in
large part, too, on the specifics of how much local IRBs
are subsequently permitted to modify or reject reviews.
We’ve worked very well with the adult CIRB because
it leaves the local IRBs a lot of room to make
changes. We’re very happy with that. Other large-
scale regional IRBs have not seemed all that great.
Limited numbers of people have oversight, and are
not involved with the institution. They don’tk n o w
the institutional, let alone the local, culture. The
adult CIRB differs from the others. It’sn a t i o n a l ,
looking at huge cancer studies all over the country;
so they develop a standard of what they expect, and
what’s in the consent. Local IRBs can then modify it,
which they’ve allowed. It’s probably very effective.
But the larger regional IRBs are more focused on
the specifics of the study, and tend to do more with
the study itself. IRB25
Hence, the details of how more centralized models
work are important. The debate thus needs to evolve
beyond simply central vs. local, to examine to what
degree, and how exactly different models might operate.
This interviewee feels that knowledge of local institu-
tional culture is important as well (though not the
intent of the regulations).
Multi-site studies may also vary in structure, such that
a primary site may simply take the lead, and other IRBs
might thereby cede to it - though not always. An insti-
tution could potentially agree in advance to rely on
another institution’s IRB, but then disagree with a parti-
cular review. One IRB agreed to make an exception, and
accept an outside review because this IRB was an “add-
on,” and did not want to be “the tail wagging the dog.”
We accepted their consent form and protocol, and
told our investigator, “You don’t have to redo it.” It
was excellent. But that was an exception to the rule...
Really the only o n e ,b e c a u s ew ew e r ea tt h ep o i n t ,
otherwise, of being the tail wagging the dog. The
other medical center was taking the lead, and doing
most of the research. Our researchers just sort of
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exception in this case.” IRB8
Local IRBs may simply not want to cede much, if any,
control to a more central institution. Ceding responsibil-
ity may be hard legally, ethically, and potentially emo-
tionally, raising fears and anxieties about losing control.
Interviewees ranged, too, in their views of for-profit
CIRBs (e.g., Western IRB). While some individuals here
relied on and respected such entities, other interviewees
questioned how these bodies could be sufficiently aware
of local communities and values. Concerns arose, too,
that for-profit entities might have conflicts of interest,
since they are paid to review and approve studies.
Advantages of CIRBs
As suggested above, interviewees explicitly acknowl-
edged advantages of CIRBs only rarely, but implicitly
potential advantages as well. Specifically, CIRBs with a
local option to accept, reject, or modify reviews could
“streamline” work, and save time.
Disadvantages of Local IRBs
Interviewees described local IRBs as varying in their
“colors” and “flavors,” and in how “nitpicky” vs. “user-
friendly” and “pro-research” they were, based not on
local community values, but on characteristics of the
chair and/or vocal members (e.g., whether they were
themselves researchers), and local institutional cultures
and histories. Several IRBs appeared more cautious or
“obsessive” because of experiences and/or fears of fed-
eral audits or “shut-downs” of research at their institu-
tion in the past 10 to 15 years (causing “The Reign of
Terror”). Yet interviewees generally accepted such differ-
ences between local boards as inherent aspects of the
system.
Local IRB Members as Biased in Their Views of CIRBs?
At times, in part due to the psychological and legal
issues mentioned earlier, IRBs appeared biased in favor
of local control. In articulating the benefits of local
review, interviewees often seemed to have little, if any,
sense of the status quo’s potential costs to investigators.
The chair who stated earlier that it was easier to judge
the risks and benefits that are closer (vs. “farther away”)
added:
I like the current model. I’m not sure why. I’ve never
been on regional IRBs. IRB12
He continued that in an inter-institutional research
group, in which he is engaged, he doesn’t find many var-
iations between IRBs, except merely over wording.
As an investigator, I’m involved in a consortium, and
don’t see a lot of difference between what’s accepta-
ble at one institution vs. another. There are usually
arguments over wording here and there, but not the
basic risk vs. benefit analyses of a protocol. IRB12
Though one might expect all researchers in multi-site
studies to favor CIRBs, he does not, perhaps because he
has long been an IRB member. Yet his statement under-
mines his earlier notion that local community values
play important roles here, and conflicts with the data,
mentioned earlier, that discrepancies often involve more
than wording alone. He and others also do not appear
to consider or weigh possible logistical and other costs
to PIs involved.
Other Possible Solutions
More guidance
Several interviewees were wary of CIRBs, and felt that
more guidance, not CIRBs, can help reduce ambiguities
in current regulations, and solve ongoing problems and
tensions in the present system.
Investigators think a central IRB will make things go
faster. But it doesn’t really solve problems. The 14
or so pages of regulations reflect the philosophy of
the federal government in the 1700s or 1800s: it’sa l l
about local control. Local control is good on a
school board. It isn’t very good when researchers
across the country are trying to conduct the same
study, but need to meet different standards. That
takes a lot of time, and introduces a lot of noise, and
variation in the consent, the review process, and the
regulatory oversight. The federal government or
OHRP needs to step in, and give some guidance.
They don’t have to say, “It’sg o t t ab ethis way,” but
they have to provide more guidance than there is
now. The regulations basically say: it’su pt oy o ut o
interpret things. But whati ss l i g h ti n c r e a s eo v e r
minimal risk in pediatric studies? On a whole host
of issues, we have absolutely no guidance, which
contributes to very heterogeneous reactions of IRBs
handling exactly the same studies. IRB5
More regional IRBs?
In the debates over whether to establish more centra-
lized or regionalized IRBs, several interviewees suggested
that one alternative would be simply to have more
regional IRBs, gathering more local information. For
instance, the chair who saw a current “city-wide” IRB
(which reviews only certain, but not all protocols) as
“too strict” nonetheless perceived potential advantages
in wider use of such municipal-wide entities - though
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We have so many institutions here, that it would be
interesting to have a city-wide IRB. IRB25
Conclusions
Interviewees tended to have strong views concerning
CIRBs, and highlighted advantages and disadvantages of
both local and centralized processes. Overall, however,
these local IRB chairs, administrators, and members
overwhelmingly supported local over centralized IRBs.
Specifically, these interviewees argued that local IRBs
can better provide local knowledge of subjects and of
PIs, and “curbside consults” with PIs that can facilitate
mutual trust, potentially decreasing non-compliance.
Local IRBs may also appreciate local institutional cul-
ture. While a few interviewees acknowledged that the
current system can impede multi-site studies, and that
CIRBs could potentially reduce duplication of efforts
and streamline work, in the end all interviewees sup-
ported the continuation of local IRBs in some form.
Importantly, these interviewees also suggested that the
quality of CIRBs can range considerably. Many of these
IRBs had had experience with the centralized reviews of
the NCI for adult oncology trials, and of the Pediatric
Oncology Group, and of for-profit IRBs, and felt that
the nature and outcome of centralized IRBs can vary,
depending on who happens to be members of the com-
mittee. Of note, both local and centralized IRBs appear
to have unintended consequences, both good and bad,
that have received little attention, and need to be more
fully taken into account.
These interviewees felt that the local knowledge of
subjects and PIs, long-standing informal interactions
with these PIs, and consequent trust and IRB “comfort”
are important. PIs may interact more fully and infor-
mally, and hence in many ways effectively, with local
than centralized IRBs. In general, interactions can
depend on both the quantity and quality of information
exchanged. Communication early in a process can lead
to avoidance of later difficulties (e.g., expending efforts
on what turn out to be unfruitful approaches in addres-
sing research ethics issues).
IRBs here believe that accessibility to PIs may enhance
trust. Local IRBs can potentially play vital roles in pro-
viding “curbside consults” that may establish and main-
tain mutual trust that may, in turn, help ensure the
protection of human subjects. Hence, informal interac-
tions in an institution, established over time, can be cri-
tical. However, future research is needed to explore how
PIs themselves view these issues - whether they agree,
and what factors they feel increase or decrease their
trust of IRBs.
Though usually seen in debates as fixed, objective,
bureaucratic entities, IRBs emerge here as engaged in
complex, dynamic social systems, shaped by particular-
ized, individual relationships with PIs, institutions, and
communities.
These social bonds include not only colleagues and
PIs, but patient populations as well. IRB chairs and
members, many of whom are themselves physicians, felt
a sense of commitment to “their patients” - i.e., those of
their institution - and felt that entrusting these patients
to a distant, “anonymous” CIRB represented an abdica-
tion of this responsibility. This sense of commitment
highlights how belonging to a community can generate
deeply personal social, as well as moral, bonds that can
potentially enhance protection of subjects. Belief in this
sense of local bonds may fuel local resistance to CIRBs.
But presumably, an ethical obligation to safeguard
research subjects as much as possible should exist on
C I R B sa sw e l l-i . e . ,b et h es a m ef o rp a r t i c i p a n t se l s e -
where, too. Researchers should presumably not protect
subjects at their home institution more than participants
at another medical center.
T h ec l o s ek n o w l e d g eo fP I sa n dp a t i e n t st h a tl o c a l
IRBs offer does not appear to have been the intent of
the regulations. Rather, such IRBs were established to
reflect local community laws and values. But between
IRBs, discrepancies that arise may result instead from
differences in local knowledge, or institutional history
and culture, and personalities and idiosyncrasies of par-
ticular IRB chairs and/or vocal members, or may be far
more complex and seem relatively random - i.e., not
systematically resulting from clear, objectifiable factors.
Further research is needed as well to probe more fully
these potential underlying causes of discrepancies.
High levels of communication and trust between IRBs
and PIs, and IRB knowledge of details about subject
populations, and commitment to these individuals, are
nonetheless valuable. But difficult tradeoffs then ensue.
Local IRBs may enhance reviews (e.g., providing local
knowledge of PIs) and/or generate costly and unneces-
sary discrepancies. However, it is not clear how to bal-
ance these advantages (which were not the intent of the
regulations) against the disadvantages of local IRB
reviews (e.g., inter-IRB discrepancies). Whether these
advantages of local IRB review offset the resultant pro-
blems, and whether a system can be implemented that
yields these benefits, while avoiding the disadvantages of
local review, is not evident. Needs emerge to ensure
that details of local knowledge are sufficiently incorpo-
r a t e di n t or e v i e w s ,b u th o wt od os os u c ht h a tr e v i e w s
do not also become duplicative is unclear.
Within the US, it is unknown, too, how often commu-
nity values significantly differ between IRBs in ways that
do or should shape specific IRB decisions. No systematic
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The fact that institutional and personality issues can
play roles is not surprising, given the complex dynamic
social processes involved. But while interviewees, in
arguing for local IRB review, frequently aver that varia-
tions exist in community values, the examples that the
men and women provide here appear instead often to
reflect differences in local knowledge, and potentially
other factors. Further research is thus vital on other, lar-
ger samples concerning how often, in what ways, and to
what degree inter-IRB discrepancies result from differ-
ences in local values vs. local knowledge and other
causes.
These interviewees’ reasons for favoring local IRBs
reflect attitudes (e.g., local knowledge of PIs and study
populations), rather than objective evidence of improved
human subject protection. Yet some of these attitudinal
factors may influence protection of human subjects (the
goal of IRB review) not directly, but indirectly. Systema-
tic studies demonstrating the degrees to which IRBs in
fact reduce concrete harms to subjects are still lacking.
Granted, such evidence may be difficult to collect since
such injuries related to deficiencies in research ethics
may be relatively rare and hard to measure. Subjects
may be hurt due to serious, unanticipated adverse events
in a study protocol (e.g., previously unknown side effects
of an experimental drug), but these may not be due to
deficiencies in research ethics per se.
Nonetheless, enhanced local knowledge of subject
populations and PIs (e.g., awareness that certain popula-
tions are vulnerable, and that certain PIs have been rela-
tively more “cavalier” in the past) is important as it can
facilitate human subject protection by raising caution in
reviewing certain protocols. Such increased cognizance
may heighten human protection indirectly - even if not
directly and measurably - by decreasing the likelihood of
threats to research ethics occurring.
Relatedly, at first glance, two findings here may appear
contradictory: on the one hand, interviewees support
local IRBs, not because such local entities reflect com-
munity values, but because such local IRBs can facilitate
interactions with PIs and provide local knowledge of PIs
and subjects. Yet on the other hand, these interviewees
are nonetheless wary that CIRBs may insufficiently
attend to local values. In the end, however, these two
sets of beliefs are not mutually exclusive. Rather, the
existence of significant differences in local community
values may be somewhat illusory, more than empiri-
cally-based. Despite this absence of empirical evidence,
interviewees still support this rationale, because it is sti-
pulated in 45-CFR-46, and appears to justify their exis-
tence, efforts, and expense.
These interviews also underscore several potential dis-
advantages of CIRBs. While some critics of IRBs may
see these centralized entities as panaceas, certain pro-
blems appear likely to continue. CIRBs may be as sub-
jective as local IRBs - i.e., shaped by the particular
views, biases, or predilections of whoever happens to be
the chairs and membership (e.g., how “nit-picky” vs.
“user-friendly” and pro-research these individuals are).
These interviewees express, too, deep wariness and
suspicion of CIRBs, and of “anonymous government
bureaucracies,” reflecting the same apprehension that
underlies broader political caution of federal govern-
ment involvement and notions of “states’ rights.” Yet as
a result, local IRBs may resist efforts at centralization,
potentially impeding the spread, efficiencies, and accep-
tance of such efforts. Given tensions due to interviewees’
concerns - whether valid or not - that CIRBs will insuf-
ficiently incorporate local knowledge, other two-tiered
models may be advantageous. Such mechanisms might
still include some local review (e.g., having local
reviewers contribute to CIRB discussions). But how such
mechanisms would operate - e.g., in multi-site studies
being reviewed by a CIRB - and how much such “dual
reviews” would decrease expenses and eliminate discre-
pancies, are unclear.
Granted, as members of local IRBs, these interviewees
may, in certain ways, be biased in their assessments.
The IRB chairs and administrators here receive support
- even if it is only part of their salary - for their work in
the status quo, which they thus may be invested in
maintaining. Future research on IRB members’ views on
these issues should take this potential limitation into
account, and explore it more fully.
These data have additional implications for policy as
well. Current debates about local vs. central reviews do
not appear to reflect the complexities here, but should.
These debates need to shift from focusing simply on a
binary decision of local vs. centralized (or regionalized)
IRBs, to explore specifically how different models do
and could function; what the relative advantages and
disadvantages of each are, and how to balance these;
what obstacles might arise in attempting to institute any
change; and whether and how these barriers ought to be
overcome. Policy-makers and others thus need to care-
fully consider the difficult tradeoffs that emerge here (e.
g., when, if ever, the benefits of local IRB knowledge off-
set the delays and obstacles of multiple local IRB
reviews). The debate has not generally addressed these
dilemmas, but needs to do so to advance future
discussions.
Policy questions surface as well concerning whether,
how much, and in what ways to arrange for central and
regional IRBs to interact with PIs closely, frequently,
and effectively. At local IRBs, these interactions may be
based on long-standing relationships and mutual trust,
allowing for informality that can facilitate
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establish such relationships is critical. To do so at a fed-
eral level may be impossible, since these interactions
may then diminish “informality”. The responses of a fed-
eral bureaucrat would presumably be “official” in a way
that local “curbside consults” are not. But potentially,
CIRB reviews can incorporate additional local knowl-
edge in varying ways and to varying degrees, and hence,
review options need not be simply dichotomous - local
vs. central, all or none. Rather, enhanced local input and
reviews could be made available to CIRBs.
Many of the characteristics of CIRBs explored here
apply, too, to regional IRBs, which appear more com-
mon in other countries, and seem a logical middle-
ground - permitting “local knowledge” and trust, while
still streamlining the review process. But the current
data suggest possible limitations of such a regional sys-
tem as well. Vast differences can arise in regional IRBs,
depending on exactly how regional these entities are (e.
g., whether they cover a city, state, or large part of an
entire country). These interviews suggest needs for addi-
tional research and guidance on, and possible further
establishment of, such regional IRBs. The specific
degrees to which such regional organizations indeed
provide the advantages and avoid the disadvantages of
both local and central IRBs require close investigation.
Questions emerge, too, as to which studies should be
reviewed through central, regional, or local boards.
While some critics recommend CIRBs for multi-site stu-
dies (where the costs of multiple, conflicting IRB reviews
appear highest), single-site studies might then be left
wholly to local review, and prey to local biases, and
potential impediments. Subjects in single-site and multi-
site studies may then receive different kinds or degrees
of protection. Hence, it may make sense to consider
CIRBs for single-site studies as well, though doing so
may be harder to justify. These issues require further
examination and discussion as well.
Given interviewees’ resistance to CIRBs as structural
solutions in efforts to improve IRBs, altering local IRB
attitudes may be more achievable, and hence in need of
further consideration. For instance, helping IRB mem-
bers to become more cognizant of their own potential
biases and assumptions that are not evidence-based
might be beneficial.
These data have several additional implications for
future research as well. Several “myths” about both local
and central IRBs - concerning their respective advan-
tages and disadvantages - may exist. As policy-makers
and others contemplate increased CIRBs, it is critical to
have as full an understanding of the potential pros and
cons of these entities as possible. Studies are needed to
explore more fully, among larger samples, how IRB
chairs, members, and staff view and interact with local
and centralized boards; what the roles and effects of
informal communication are; how frequently and in
what ways local IRBs in fact alter CIRB recommenda-
tions; how to develop and assess such models of CIRBs
to enhance trust and overcome wariness; and how to
guide the development of any such policy initiatives.
Further research is crucial, too, to assess how often IRBs
interpret and apply regulations differently in ways that
reflect psychological and institutional issues vs. differences
in community values, and whether and how educational
or other interventions can make IRB interpretations more
uniform and less discrepant due to personalities and local
institutional histories. Further data on actual IRB practices
vs. assumptions can help guide these debates.
This study has several potential limitations. These data
are based on in-depth interviews with individual IRB
members and chairs, and did not include direct observa-
tion of IRBs making decisions, or investigation of IRB writ-
ten records. Future research can also observe IRBs and
examine such records. However, such additional data may
be difficult to obtain since, anecdotally, IRBs have at times
required that researchers obtain consent from all IRB
members, as well as from the PIs and funders of protocols.
These interviews probed respondents’ views at present
and in the recent past, but not prospectively over time
to assess whether they changed their views, and if so,
why. Future research can explore these issues as well.
It is possible that response bias may have occurred here
as well - i.e., that individuals who agreed to participate
may differ systematically from those who did not. Those
who responded may be more or less favorably inclined
toward the status quo. However, there is no evidence
that such differences exist either way. Further research
can, however, also examine these possibilities among
additional, larger samples of IRB chairs and members.
This study also did not assess views of CIRB chairs or
members, but future research can examine their perspec-
tives as well. In addition, among interviewees here,
experiences with CIRBs varied in amount and type - e.g.,
from for-profit IRBs to governmental, from extensive to
minimal interactions (i.e., from dealing with one to more
than one CIRB, concerning one to more than one proto-
col), and from harmonious to problematic and conflic-
tual. A few interviewees did not have direct experience,
but knew of other IRB members or chairs at their own or
at other institutions who had had such interactions.
Nonetheless, the attitudes of all of these interviewees
are vital, since these may reflect prevalent views among
local IRBs more generally, and highlight wider concerns,
fears, and misconceptions. These perspectives are all cri-
tical, and need to be addressed, as efforts to centralize
IRBs will no doubt continue.
In sum, these data highlight the intricate, complex tra-
deoffs and uncertainties that may be involved in
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CIRBs, which should be considered in ongoing discus-
sions concerning these and other approaches to improv-
ing human research subject protection. While some
critics herald CIRBs as a virtual cure-all to current pro-
blems with IRBs, interviewees here underscore the
importance of advancing the current debate from
whether local or centralized IRBs should be instituted,
to more nuanced analyses of how these and other mod-
els may best be used. Careful ongoing investigation and
discussion of these issues are vital.
Appendix
Sample Questions from Semi-Structured Interview
Note: Additional follow-up questions were asked, as
appropriate, with each participant.
▪ How do you define research integrity (RI)? How has
your IRB approached RI issues? What have been the
most difficult cases concerning RI that your IRB has
faced? How did your IRB respond?
▪ Do you think IRBs differ in their views or
approaches toward RI, and if so, when, how, and why?
Do you think IRBs apply standards regarding RI differ-
ently, and if so, when, how, and why?
▪ What factors do you think affect how IRBs make
decisions about RI and other areas?
▪ What do you think makes an IRB work well or not
in monitoring and responding to RI?
▪ Does your IRB encounter tensions with PIs about RI
or other related issues? If so, how, when, and why?
▪ Is your IRB more cautious about some researchers
than others? Why?
▪ What kinds of conflicts, if any, has your IRB faced
with your institution?
▪ Do you think a centralized IRB rather than local
IRBs would have advantages concerning RI and other
areas? If so, what, how, and why?
▪ Should other regulations or guidelines concerning
IRB reviews of RI or other areas be developed, and if so,
what?
▪ What do you think could be done to improve inter-
actions with PIs concerning RI and related issues?
▪ Do you have any other thoughts about these issues?
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